Want to see SE:FLUI full AI Analyst Report?
Fluicell AB (FLUI) Stock Price & Analysis
FLUI Stock Chart & Stats
- Day’s Range
- SEK 27.70 - SEK 27.90
- 52-Week Range
- SEK 7.65 - SEK 67.20
- Previous Close
- SEK 27.70
- Volume
- 175.18K
- Average Volume (3M)
- 2,720
- Market Cap
- SEK 38.33M
- Enterprise Value
- SEK 43.46M
- Total Cash (Recent Filing)
- SEK 30.00K
- Total Debt (Recent Filing)
- SEK 2.00M
- Price to Earnings (P/E)
- 13.7
- Beta
- 1.07
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability Inflection
The latest TTM period shows a meaningful shift from losses to positive EBIT and net income alongside 67.4% revenue growth. If this improvement is sustained, it can strengthen operating leverage, support reinvestment, and establish a more durable earnings base.
Very High Gross Margin
A gross margin near 91.6% indicates substantial value capture in the company’s specialized products and technology-led offering. Such margin potential can provide room to fund research, sales expansion, and customer support while allowing earnings to scale faster than revenue.
Modest Leverage And Stronger Equity Base
Low leverage and a substantial equity position provide financial flexibility compared with a highly indebted structure. This balance-sheet support can help Fluicell absorb operating volatility, pursue product development, and maintain strategic options while its commercial model continues to scale.
Bears Say
Business Is Not Yet Self-Funding
Negative operating and free cash flow means reported profitability has not yet translated into internally generated funding. Continued cash burn can constrain investment capacity and increase reliance on external financing until revenue growth produces consistently positive operating cash conversion.
Long History Of Losses
The multi-year record of substantial losses makes the recent profitable TTM period less proven as a durable trend. Fluicell must demonstrate that improved revenue converts into repeatable earnings across additional reporting periods before its earnings power can be considered established.
Profitability Durability Remains Unproven
The company’s small biotech profile and limited history of positive results leave uncertainty around the persistence of current margins. If revenue does not scale consistently, high gross margin may not prevent earnings volatility or renewed operating losses over the coming quarters.
FLUI FAQ
What was Fluicell AB’s price range in the past 12 months?
What is Fluicell AB’s market cap?
When is Fluicell AB’s upcoming earnings report date?
How were Fluicell AB’s earnings last quarter?
Is Fluicell AB overvalued?
Does Fluicell AB pay dividends?
What is Fluicell AB’s EPS estimate?
How many shares outstanding does Fluicell AB have?
What happened to Fluicell AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fluicell AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Fluicell AB
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carolina Trjulja
- Employees
- 11
- Website
- www.fluicell.com
- Address
- Flöjelbergsgatan 8C, Mölndal, VG, 431 37, SE
Fluicell AB (FLUI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 5 | 7 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 6 | 0 | 6 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:XINTXintela AB | ||
| SE:BIOVIC.BBiovica International AB Class B | ||
| SE:NXTCLNextCell Pharma AB | ||
| SE:BIOWKSBio-Works Technologies AB | ||
| SE:FLUOFluoGuide A/S |